FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Prostate cancer screening may benefit people with Lynch syndrome
Relevance: High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with Lynch syndrome
Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsStudy : More is not better: PARP dose can be safely reduced for people with ovarian cancer
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People taking a PARP inhibitor for ovarian cancer maintenance therapy
Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)
Este artículo está disponible en español.
Read MoreUpdate : Strategies for managing pancreatic cancer pain
Most relevant for: People with pancreatic cancer who are dealing with related pain.
Abdominal pain is often a severe, ongoing symptom of pancreatic cancer, yet little research has been done on how to best reduce this pain. The authors of this review discuss current strategies for managing cancer-related pain and their effectiveness. (Posted 10/31/22)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Resistant starch may help prevent some cancers in people with Lynch syndrome
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with Lynch syndrome and people with a personal and/or family history that suggests Lynch syndrome
This study looked at whether a type of nutrient known as resistant starch could lower the risk of cancers in people with Lynch Syndrome. Researchers found that resistant starch can reduce the risk of non-colorectal cancers but not colorectal cancer. (Posted 10/17/22)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Study : Teens and young adults respond well to learning about familial cancer risk
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer
Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.
Read MoreUpdate : PARP inhibitors withdrawn as third-line or later treatment for recurrent ovarian cancer
Most relevant for: people with recurrent ovarian cancer who have received 3 or more prior lines of treatment and who have an inherited or tumor mutation in BRCA1 or BRCA2 or whose tumor is HRD positive
Survival data from a clinical trial signaled that PARP inhibitors may not work as well as chemotherapy for patients with recurrent ovarian cancer who have received three or more lines of treatment. As a result, FDA approvals have been withdrawn for PARP inhibitors in this setting. This does not affect PARP inhibitor approvals for use as maintenance therapy for ovarian cancer. (Posted 10/4/22)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Acupuncture may ease breast cancer treatment side effects
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People considering acupuncture for managing breast cancer treatment symptoms.
Acupuncture can ease some symptoms of breast cancer treatment. Multiple studies found that acupuncture is a safe and effective strategy to manage certain symptoms but also called for more rigorous research on the topic. (Posted 9/28/22) Este artículo está disponible en español.
Read MoreUpdate : FDA reports on new cancers linked to breast implants
Most relevant for: People with breast implants
New cancers have been found in women with both textured and smooth implants that are filled with either saline or silicone. These cancers are extremely rare. The FDA has reported cases of a type of skin cancer and blood cancers in the scar tissue that forms around breast implants. The newly reported lymphomas are different from the previously reported breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (Posted 9/27/22). Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Study : Expanding Medicaid reduced racial disparities among people with metastatic breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: People diagnosed with de novo stage 4 breast cancer and people who live in states that have not expanded Medicaid.
The Affordable Care Act allowed more people to access insurance through Medicaid. This study found the expansion of care improved survival and decreased mortality among people of color with de novo stage 4 (stage 4 at the time of initial diagnosis) breast cancer. (Posted 9/13/2022). Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.
This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors. (posted 9/6/2022)
Este artículo está disponible en español.
Read More